Find News

Filter articles

Showing 2381 to 2390 of 2541 results

C5 Congress: Myriad decision "will not" affect patenting in Europe


Aliki Nichogiannopoulou, director of biotechnology at the European Patent Office, outlined best practices for patenting antibodies at the office while speaking at the 25th C5 Congress on Biotech and Pharma Patenting in London on Wednesday.

Orrick expands IP team


Orrick Herrington & Sutcliffe LLP has expanded its IP group and hired Grace Pan as partner.

Novartis takes on Roxane Laboratories over drug application


Novartis Pharmaceuticals has filed a lawsuit against US drug manufacturer Roxane Laboratories disputing an application for a schizophrenia drug.

Takeda announces new COO


Takeda has announced that Christophe Weber, a member of GlaxoSmithKline’s global corporate executive team, will be joining the company as chief operating officer by April next year.

US reveals changes in TPP drug policy


The US government has said it is now advocating a “differential” approach to policies on patenting drugs as part of continuing trade negotiations with Pacific countries.

KKR invests $200 million in Indian injectables maker

India, US29-11-2013Mergers & acquisitions

US investment firm KKR has bought a stake in Indian pharmaceutical company Gland Pharma for approximately $200 million.

Myriad faces yet another patent battle

US28-11-2013Legal developments

Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

India considering new patent filing rules


India is considering altering its requirements for filing drug patents in a bid to create more transparency in the pharmaceutical market, it has been claimed.

Teva and Mylan settle Copaxone patent litigation in Europe

France, Netherlands, UK26-11-2013Legal developments

Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.

FDA orders 23andMe to cease PGS sales


The US Food and Drug Administration has told genetics company 23andMe to stop selling its Personal Genome Service product immediately.

Showing 2381 to 2390 of 2541 results